Search

Your search keyword '"Andersen, L. S."' showing total 121 results

Search Constraints

Start Over You searched for: Author "Andersen, L. S." Remove constraint Author: "Andersen, L. S."
121 results on '"Andersen, L. S."'

Search Results

2. A just world on a safe planet: a Lancet Planetary Health–Earth Commission report on Earth-system boundaries, translations, and transformations

3. Living within the safe and just Earth system boundaries for blue water

6. ImpACT+, a coping intervention to improve clinical outcomes for women living with HIV and sexual trauma in South Africa:study protocol for a randomized controlled trial

7. Periarticular and generalised bone loss in patients with early rheumatoid arthritis: influence of alendronate and intra-articular glucocorticoid treatment. Post hoc analyses from the CIMESTRA trial

9. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA)

10. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTRA study

12. South African Depression Scale

13. One year follow-up of a nationwide cohort of patients with inflammatory arthritis, who switched from originator to biosimilar etanercept, focusing on patients who switched back to originator. An observational DANBIO study

14. One-year treatment retention after a nationwide non-medical switch from originator to biosimilar etanercept in 2,061 patients with inflammatory arthritis followed in the DANBIO registry

17. HLA-B27 status is associated with TNFα inhibitor treatment outcomes in ankyloses spondylitis and non-radiographic axial spondyloarthritis Observational cohort study from the nationwide DANBIO registry

18. Effect of a treat-to-target strategy based on methotrexate and intra-articular betamethasone with or without additional cyclosporin on MRI-assessed synovitis, osteitis, tenosynovitis, bone erosion, and joint space narrowing in early rheumatoid arthritis:results from a 2-year randomized double-blind placebo-controlled trial (CIMESTRA)

19. This title is unavailable for guests, please login to see more information.

20. Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with in flammatory arthritis:Results from the DANBIO registry

21. Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Results from the DANBIO registry

22. Magnetic Resonance Imaging Joint Space Narrowing Is An Independent Predictor of Radiographic and MRI Damage Progression in Patients with Early Rheumatoid Arthritis

23. Three Months' Clinical Outcomes from A Nationwide Non-Medical Switch from Originator To Biosimilar Infliximab in Patients with Inflammatory Arthritis:Results from The Danbio Registry

25. Interactions between smoking, increased serum levels of anti-CCP antibodies, rheumatoid factors, and erosive joint disease in patients with early, untreated rheumatoid arthritis

27. Plasma IL-6 in early rheumatoid arthritis is associated with disease activity, joint destruction, and treatment response

28. Combination treatment with methotrexate, cyclosporine, and intraarticularbetamethasone compared with methotrexate and intraarticular betamethasone inearly active rheumatoid arthritis: an investigator-initiated, multicenter,randomized, double-blind, parallel-group, placebo-controlled study

29. (1504/280) Intraarticular Glucocorticosteroid Therapy in Early Rheumatoid Arthritis. Influence of Joint Localization and Number of Previous Injections on the Duration of Suppression of Clinical Synovitis

30. (204/204) MRI is more Sensitive to Change of Structural Joint Damage in Early Rheumatoid Arthritis than X-Ray

32. Upregulated baseline plasma CCL19 and CCR7 cell-surface expression on monocytes in early rheumatoid arthritis normalized during treatment and CCL19 correlated with radiographic progression

33. Periarticular and generalised bone loss in patients with early rheumatoid arthritis

34. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2 year randomized controlled trial (CIMESTRA)

35. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database.

36. Routine database registration of biological therapy increases the reporting of adverse events twentyfold in clinical practice. First results from the Danish Database (DANBIO)

38. ASDAS, BASDAI and different treatment responses and their relation to biomarkers of inflammation, cartilage and bone turnover in patients with axial spondyloarthritis treated with TNF inhibitors

39. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

40. Low remission rates but long drug survival in rheumatoid arthritis patients treated with infliximab or etanercept: results from the nationwide Danish DANBIO database

46. THE HUMORAL IMMUNE RESPONSE TO CHLAMYDIA TRACHOMATIS IN PATIENTS WITH ACUTE REACTIVE ARTHRITIS.

47. Renal handling of carboplatin.

49. Understanding each other���s models An introduction and a standard representation of 16 global water models to support intercomparison, improvement, and communication

Catalog

Books, media, physical & digital resources